BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23126274)

  • 1. Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
    Shen H; Tang Y; Xu X; Tang H
    Pediatr Hematol Oncol; 2013 Feb; 30(1):30-2. PubMed ID: 23126274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
    Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
    Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry.
    Nagai J; Ishida Y; Koga N; Tanaka Y; Ohnuma K; Toyoda Y; Katoh A; Hayabuchi Y; Kigasawa H
    J Pediatr Hematol Oncol; 2000; 22(1):20-6. PubMed ID: 10695817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.
    Bozzi F; Gambirasio F; Luksch R; Collini P; Brando B; Fossati-Bellani F
    Anticancer Res; 2006; 26(5A):3281-7. PubMed ID: 17094441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.
    Laurent VE; Sampor C; Solernou V; Rossi J; Gabri M; Eandi-Eberle S; de Davila MT; Alonso DF; Chantada GL
    Eur J Cancer; 2013 Sep; 49(13):2892-9. PubMed ID: 23721779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Flow cytometric analysis of cerebrospinal fluid in the diagnosis of central nervous system leukemia].
    Jiang NG; Zhu HL; Zeng TT; Su J; Zhang Y; Jia YQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):664-8. PubMed ID: 20848792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
    Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
    Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
    Subirá D; Górgolas M; Castañón S; Serrano C; Román A; Rivas F; Tomás JF
    HIV Med; 2005 Jan; 6(1):21-6. PubMed ID: 15670248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the CD56+/CD45- immunophenotype by flow cytometry in neuroendocrine malignancies.
    Bryson GJ; Lear D; Williamson R; Wong RC
    J Clin Pathol; 2002 Jul; 55(7):535-7. PubMed ID: 12101203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of CD138/syndecan-1 for multiple myeloma immunophenotypes].
    Zhuang JL; Wang X; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1023-7. PubMed ID: 16403272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients.
    Warzynski MJ; Graham DM; Axtell RA; Higgins JV; Hammers YA
    Cytometry; 2002 Dec; 50(6):298-304. PubMed ID: 12497591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new violet laser dye, Krome Orange, allows an optimal polychromatic immunophenotyping based on CD45-KO gating.
    Preijers FW; Huys E; Leenders M; Nieto L; Gautherot E; Moshaver B
    J Immunol Methods; 2011 Sep; 372(1-2):42-51. PubMed ID: 21781971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy.
    Farinola MA; Weir EG; Ali SZ
    Cancer; 2003 Aug; 99(4):240-6. PubMed ID: 12925986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
    van Velzen JF; van den Blink D; Bloem AC
    Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
    Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
    Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood.
    Jiang NG; Jin YM; Niu Q; Zeng TT; Su J; Zhu HL
    Ann Hematol; 2013 Jan; 92(1):89-96. PubMed ID: 22992980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia.
    Coustan-Smith E; Behm FG; Hurwitz CA; Rivera GK; Campana D
    Leukemia; 1993 Jun; 7(6):853-8. PubMed ID: 7684798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.